Digital Pathology Industry
The global digital pathology market size is expected to reach USD 1.73 billion by 2030, registering a CAGR of 8.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to witness exponential growth owing to rising prevalence of chronic diseases aided by increasing demand for accurate diagnostics. Chronic diseases affect nearly one in every three adults. Whereas, according to the CDC, in the U.S., approximately, 51.8% of adults have at least one chronic disease. Digital pathology, including molecular tissue profiling, biobanking, tissue microarray analysis, and molecular biology, plays an important role in the drug development pipeline and companion diagnostics. Growing demand for high-quality tissue samples in tissue-based biomarker research is expected to drive technology adoption over the forecast period.
Increasing adoption of telepathology with the launch of newer versions of the technology, such as in June 2022, Tribun Health launched TeleSlide Patho 5, an online telepathology platform used for providing clinical and timely expertise to patients. Moreover, the market is expected to see intense competition in the near future as companies adopt more stringent strategies to compete. Moreover, technological advancements, such as the digitization of pathology lab makes the specialty more efficient, the specimen more reproducible, and pathologists' work easier. In past few years, several breakthrough advancements have provided a significant boost to market growth.
For instance, in September 2021, Paige received FDA approval for Paige Prostate, an AI solution for the detection of prostate cancer. The product is the first AI-enabled pathology product to gain marketing authorization. This was further followed by the collaboration of F. Hoffmann-La Roche Ltd. with Ibex in October 2021 for the development of artificial intelligence-based pathology applications for the improvement of patient care. Furthermore, major players are adopting strategies like collaborations and partnerships with a focus on technological advancements, such as robotic light microscopy, digital imaging, multiple fiber optic communications, and computerization, to enhance the adoption of digital pathology.
Gather more insights about the market drivers, restrains and growth of the Global Digital Pathology market
Digital Pathology Market Segments Highlights:
- Based on product, The device segment held the largest share of 51.72% in 2023 and is anticipated to grow at a lucrative growth rate during the projected period. The device segment includes a slide management system and scanner. The segment growth is attributed to the increasing adoption of digital pathology in academic research activities with enhanced resolution
- Based on application, Disease diagnosis is anticipated to witness the fastest growth rate from 2024 to 2030 due to an increasing prevalence of chronic diseases and demand for noble diagnosis techniques
- In terms of end-use, The hospitals segment dominated the market in 2023 with a share of 36.7% due to the growing incorporation of digital pathologies in healthcare settings for efficient disease diagnosis
- North America dominated overall market in 2023 with a share of 40.7%, due to the presence of well-established digital infrastructure and several technological advancements pertaining to the incorporation of technology in healthcare settings
Digital Pathology Market Report Segmentation
Grand View Research has segmented the global digital pathology market based on product, type, application, end-use, and region:
Digital Pathology Product Outlook (Revenue, USD Billion, 2018 - 2030)
- Software
- Device
- Scanners
- Slide Management System
- Storage System
Digital Pathology Type Outlook (Revenue, USD Billion, 2018 - 2030)
- Human Pathology
- Veterinary Pathology
Digital Pathology Application Outlook (Revenue, USD Billion, 2018 - 2030)
- Drug Discovery & Development
- Academic Research
- Disease Diagnosis
- Cancer Cell Detection
- Others
Digital Pathology End-use Outlook (Revenue, USD Billion, 2018 - 2030)
- Hospitals
- Biotech & Pharma Companies
- Diagnostic Labs
- Academic & Research Institutes
Digital Pathology Regional Outlook (Revenue, USD Billion, 2018 - 2030)
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- ROE
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- RoAPAC
- Latin America
- Brazil
- Mexico
- Argentina
- RoLATAM
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Key Digital Pathology Company Insights
- Leica Biosystems Nussloch GmbH (Danaher)
- Hamamatsu Photonics, Inc.
- Koninklijke Philips N.V.
- Olympus Corporation
- Hoffmann-La Roche Ltd.
- Mikroscan Technologies, Inc.
- Inspirata, Inc.
- Epredia (3DHISTECH Ltd.)
- Visiopharm A/S
- Huron Technologies International Inc.
- ContextVision AB
- CellaVision
- HANGZHOU ZHIWEI INFORMATION TECHNOLOGY CO. LTD. (MORPHOGO)
- West Medica Produktions- und Handels- GmbH (West Medica)
- aetherAI
- IBEX (IBEX MEDICAL ANALYTICS)
- SigTuple Technologies Private Limited
- Morphle Labs, Inc
- Bionovation Biotech, Inc.
Order a free sample PDF of the Digital Pathology Market Intelligence Study, published by Grand View Research.